Data Sheet (Cat.No.T7635)

TargetMol

Raclopride

Chemical Properties



CAS No. : 84225-95-6

Formula: C15H20Cl2N2O3

Molecular Weight: 347.24

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Raclopride is a selective antagonist of dopamine D2/D3 receptor.
Targets(IC50)	Dopamine Receptor
In vivo	Raclopride passes the blood brain barrier and can be used in in vivo binding and autoradiography studies of the dopamine system under normal and pathological conditions such as Huntington's disease[1]

Solubility Information

Solubility	DMSO: 100 mg/mL (287.99 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.52 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8799 mL	14.3993 mL	28.7985 mL
5 mM	0.576 mL	2.8799 mL	5.7597 mL
10 mM	0.288 mL	1.4399 mL	2.8799 mL
50 mM	0.0576 mL	0.288 mL	0.576 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ginovart, N. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: Understanding the true mechanism. Mol. Imaging Biol. 7, 45-52 (2005).
Håkan Hall, Christer Köhler, Gawell L , et al. Raclopride, a new selective ligand for the dopamine-D2 receptors[J]. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12(5):559-568.
Benedetto L, Rivas M, Cavelli M,et al.Microinjection of the dopamine D2-receptor antagonist Raclopride into the medial preoptic area reduces REM sleep in lactating rats[J].Neurosci Lett. 2017 Oct 17;659:104-109.